Sunday November 22 2009 | Biotechnology feed | All feeds
|
|
Fusion Antibodies Ltd
Download detailed PDF Members: Fusion, established in 2001 as a spin-out from Queen’s University Belfast, has won a host of awards for its leading-edge technology platform FET (Fusion Expression Technology). This enabling technology accelerates the validation of targets from DNA sequence through to recombinant protein expression. Fusion generates target specific antibodies from protein antigens with capability, through its antibody engineering know-how, to modify their characteristics to increase efficacy. These technologies and associated microbiological techniques, in addition to supporting Fusion’s own therapeutic and diagnostic R&D, are offered as a service to pharmaceutical, biopharmaceutical and academic researchers, allowing them to achieve their goals faster and more cost effectively. Fusion has expertise in producing specific antibodies for therapeutic, diagnostic and theranostic applications.
This page has been viewed 565 times since April 2007, the link to the organisation's website has been followed 68 times Recent Search Terms used to find this page: fusion antibodies | fusion antibodies | fusion antibodies | fusion antibodies | fusion antibodies | Fusion Antibodies | fusion an | . Search for more companies in Belfast Search for more companies in Northern Ireland This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Fusion Antibodies Ltd | |||||||||||||||||||||||||||||||||||||||||||||||||
|